Comparison of Bezafibrate Versus Lovastatin or Lowering Plasma Insulin, Fibrinogen, and Plasminogen Activator Inhibitor-1 Concentrations in Hyperlipemic Heart Transplant Patients

Accelerated coronary artery disease is the most serious obstacle to long-term survival in heart transplant recipients. Hyperlipemia, hyperinsulinism, and changes in endothelial cell hemostatic function have been implicated in cardiac allograft vascular disease. Both lovastatin and bezafibrate are safe, effective, and well tolerated therapies for hyperlipidemia. Our study compares the effect of these lipid-lowering drugs in 21 patients with post-heart transplantation hyperlipidemia on different risk factors related to insulin resistance syndrome. Patients were given the same diet for 3 months, then randomized to lovastatin or bezafibrate for a period of 8 weeks, and crossed over to an additional 8 weeks of either bezafibrate or lovastatin. Baseline parameters were also compared with those of a control group of healthy subjects and after both periods of pharmacologic treatment. Transplant patients had higher insulin (35 ± 3 vs 24 ± 3 μIU/L), fibrinogen (298 ± 15 vs 261 ± 14 mg/dl), and plasminogen activator inhibitor-1 (PAI-1) (17 ± 2 vs 11.7 ± 2 arbitrary units/ml) plasma levels than controls. Significant decreases in insulin (−37 ± 3%), fibrinogen (−12 ± 4%), and PAI-1 plasma levels (−18 ± 12%) were only observed after bezafibrate treatment. In conclusion, bezafibrate decreases plasma insulin, fibrinogen, and PAI-1 in hyperlipidemic heart transplant recipients.